What's new

ICH Guideline M13B on bioequivalence for immediate release solid oral dosage forms - additional strengths - Step 2b

ICH Guideline M13B on bioequivalence for immediate release solid oral dosage forms - additional strengths - Step 2b

Apr 9, 2025 - 09:43
 0
ICH Guideline M13B on bioequivalence for immediate release solid oral dosage forms - additional strengths - Step 2b
Read More

Tags:

Previous Article

INDA announces four industry leaders to join 2025 board of directors

Next Article

ICH Guideline M13B on bioequivalence for immediate-release solid oral dosage for...

Related Posts

Human medicines European public assessment report (EPAR): Kayfanda, odevixibat, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 10, 2025  0

EMEA-003488-PIP01-23

EMEA-003488-PIP01-23

Feb 13, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Edarbi, Azilsartan medoxomil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vascular disorders, PIP number: P/0053/2024

Opinion/decision on a Paediatric investigation plan (PI...

Apr 2, 2025  0